On the other hand, enhanced expression of the Fz antagonist sFRP2 reduced glioma invasion by decreasing β-catenin tyrosine phosphorylation and downregulating matrix metalloprotease-2 (MMP-2) [39]. The gene discussed is MMP2; the disease is central nervous system cancer.